Found: 7
Select item for more details and to access through your institution.
Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine D<sub>2</sub>-Based Pharmacological Class Effect Query Defined by FAERS.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 12, p. 1113, doi. 10.1007/s40261-022-01218-7
- By:
- Publication type:
- Article
Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS.
- Published in:
- Clinical Drug Investigation, 2021, v. 41, n. 12, p. 1067, doi. 10.1007/s40261-021-01094-7
- By:
- Publication type:
- Article
Understanding Antipsychotic Drug Treatment Efects: A Novel Method to Reduce Pseudospeciicity of the Positive and Negative Syndrome Scale (PANSS) Factors.
- Published in:
- Innovations in Clinical Neuroscience, 2017, v. 14, n. 11/12, p. 54
- By:
- Publication type:
- Article
A Novel Method for Deriving Adverse Event Prevalence in Randomized Controlled Trials: Potential for Improved Understanding of Benefit-Risk Ratio and Application to Drug Labels.
- Published in:
- Advances in Therapy, 2024, v. 41, n. 1, p. 152, doi. 10.1007/s12325-023-02695-8
- By:
- Publication type:
- Article
Interoperability Verification in ISO 18000-7 Active RFID Systems: Experimental Setup and Results.
- Published in:
- Wireless Personal Communications, 2013, v. 68, n. 3, p. 619, doi. 10.1007/s11277-011-0472-7
- By:
- Publication type:
- Article
Interoperability Test Methodology for ISO 18000-7 Active RFID.
- Published in:
- Wireless Personal Communications, 2012, v. 65, n. 2, p. 253, doi. 10.1007/s11277-011-0248-0
- By:
- Publication type:
- Article
Transformed PANSS Factors Intended to Reduce Pseudospecificity Among Symptom Domains and Enhance Understanding of Symptom Change in Antipsychotic-Treated Patients With Schizophrenia.
- Published in:
- Schizophrenia Bulletin, 2018, v. 44, n. 3, p. 593, doi. 10.1093/schbul/sbx101
- By:
- Publication type:
- Article